Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference
WAYNE, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics (NASDAQ: ACRS) announced its participation in the Jefferies Virtual Healthcare Conference on June 3, 2020, at 1:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
WAYNE, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics (NASDAQ: ACRS) announced its participation in the Jefferies Virtual Healthcare Conference on June 3, 2020, at 1:00 p.m. ET. The presentation will provide a company overview, which can be accessed via a live audio webcast on Aclaris’ website, with an archived version available for 30 days. Aclaris is dedicated to treating immuno-inflammatory diseases, featuring a diverse portfolio that includes a late-stage drug candidate supported by a strong R&D initiative.
Details
News Market Reaction – ACRS
The recorded move for ACRS in the trading session of this news was +1.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:00 p.m. ET.
A live audio webcast of the presentation may be accessed through the Events section of Aclaris’ website, www.aclaristx.com. An archived version of the webcast will be available for 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a physician-led biopharmaceutical company committed to addressing the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company’s diverse and multi-stage portfolio includes one late-stage investigational drug candidate and a pipeline powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn or Twitter @aclaristx.
Aclaris Contact
investors@aclaristx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.